Insmed reported $30.37M in Gross Profit on Sales for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acelrx Pharmaceuticals ACRX:US $ -529000 33K
Alexion Pharmaceuticals ALXN:US $ 1511.1M 71.5M
Alimera Sciences ALIM:US $ 9.65M 2.13M
Biomarin Pharmaceutical BMRN:US $ 374.63M 8.77M
Dynavax Technologies DVAX:US $ 58.71M 43.22M
Flexion Therapeutics FLXN:US $ 18.5M 1.44M
Gilead Sciences GILD:US $ 5062M 961M
Insmed INSM:US $ 30.37M 183K
Novartis NVS:US $ 9540M 679M
Regeneron Pharmaceuticals REGN:US $ 2220.7M 150.9M
Sarepta Therapeutics SRPT:US $ 124.58M 1.85M
Seattle Genetics SGEN:US $ 267.85M 271.69M
Ultragenyx Pharmaceutical RARE:US $ 94.21M 8.15M
Vertex Pharmaceuticals VRTX:US $ 1531.98M 107.26M